Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated with new standard regimens are still scarce. Thus, we aimed at assessing the incidence and clinical impact of KRAS mutations in a real-life population of advanced-NSCLC, exploring the prognostic significance of distinct alterations.
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study / Mazzaschi, Giulia; Perrone, Fabiana; Minari, Roberta; Verzè, Michela; Azzoni, Cinzia; Bottarelli, Lorena; Pluchino, Monica; Armillotta, Maria Pia; Ubaldi, Annalisa; Altimari, Annalisa; Gruppioni, Elisa; Sperandi, Francesca; Andrini, Elisa; Guaitoli, Giorgia; Bettelli, Stefania; Longo, Lucia; Bertolini, Federica; Barbieri, Fausto; Pagano, Maria; Bonelli, Candida; Tagliavini, Elena; Nicoli, Davide; Ubiali, Alessandro; Zangrandi, Adriano; Trubini, Serena; Proietto, Manuela; Gnetti, Letizia; Tiseo, Marcello. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - 23:7(2022), pp. e478-e488. [10.1016/j.cllc.2022.07.005]
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study
Mazzaschi, Giulia;Minari, Roberta;Azzoni, Cinzia;Ubaldi, Annalisa;Gnetti, Letizia;Tiseo, Marcello
2022-01-01
Abstract
Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated with new standard regimens are still scarce. Thus, we aimed at assessing the incidence and clinical impact of KRAS mutations in a real-life population of advanced-NSCLC, exploring the prognostic significance of distinct alterations.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
